Jump to navigation
About
Mission and Values
Leadership Team
Board of Directors
Medical Advisors
Focus
Hyperoxaluria
Systemic Oxalosis
Hyperuricemia
Publications
Products
Reloxaliase
ALLN-346
Pipeline
FAQs
Investors
Overview
News Releases
Events and Presentations
Stock Information
Analyst Coverage
Corporate Governance
SEC Filings
Shareholder Services
Careers
Contact
Home
Dedicated to Treating Patients
With Rare and Severe
Metabolic Diseases
Utilizing the GI Tract
to Reduce the Burden
of Metabolic Disease
Understanding
Metabolic Diseases
that Affect the Kidney
News
June 28, 2019
Allena Pharmaceuticals Announces $10.0 Million Registered Direct Offering of Common Stock
Read more
about Allena Pharmaceuticals Announces $10.0 Million Registered Direct Offering of Common Stock
June 21, 2019
Allena Pharmaceuticals Showcases Reloxaliase and Enteric Hyperoxaluria Program at OHF International Hyperoxaluria Workshop
Read more
about Allena Pharmaceuticals Showcases Reloxaliase and Enteric Hyperoxaluria Program at OHF International Hyperoxaluria Workshop
June 4, 2019
Allena Pharmaceuticals Announces Interim Results from Study 206 of Reloxaliase in High Risk Patients with Advanced Oxalate Disorders
Read more
about Allena Pharmaceuticals Announces Interim Results from Study 206 of Reloxaliase in High Risk Patients with Advanced Oxalate Disorders
